Paul Mitchell
Medical · Palm Springs, CANPI 1265668180
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (38.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 73.0% of it on its own, with 12 other manufacturers making up the rest. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $83.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$14K
- Curonix LLC$2K
- AbbVie$1K
- MML US, Inc.$400
- Painteq LLC$400
- Relievant Medsystems, Inc.$368
- plus $411 from 7 others
What the payments were for
- Speaking & faculty fees$4,31323%
- Travel & lodging$7,09938%
- Food & beverage$7,30239%
- Education$981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 105 | $13,740 |
| Curonix LLC | 15 | $2,035 |
| AbbVie(2 entities) | 55 | $1,458 |
| MML US, Inc. | 4 | $400 |
| Painteq LLC | 19 | $400 |
| Relievant Medsystems, Inc. | 3 | $368 |
| Hikma Pharmaceuticals USA | 7 | $135 |
| Collegium Pharmaceutical, Inc. | 6 | $95 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $68 |
| Dexcom, Inc. | 2 | $40 |
| Redhill Biopharma Inc. | 2 | $31 |
| Pfizer | 2 | $30 |
| Virtus Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,812 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 22 | $15,094 |
| ZtlidoLidocaine | 23 | $12,076 |
| OxycontinOxycodone Hcl | 17 | $11,213 |
| MovantikNaloxegol Oxalate | 24 | $9,474 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 338 | $8,270 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 162 | $5,593 |
| Lidocaine | 41 | $4,628 |
| Buprenorphine | 21 | $4,513 |
| Diclofenac Sodium | 99 | $4,329 |
| Gabapentin | 274 | $3,479 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $2,617 |
| Morphine Sulfate ErMorphine Sulfate | 65 | $1,680 |
| Oxycodone Hcl | 50 | $1,104 |
| Pregabalin | 69 | $1,006 |
| Baclofen | 95 | $859 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $95 | $15,09422 claims |
| Redhill Biopharma Inc.Movantik | $31 | $9,47424 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate | $135 | $7,37149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in Palm Springs
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- David DoriguzziLancaster$166K
- Deirdre MoxleyFullerton$149K
- Linda RankLadera Ranch$105K
- Cheryl KyinnSan Diego$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.